Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Feb

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Acral Melanoma Ancestry and Genetics Impact Outcomes

Inequalities in Use of Minimally Invasive Surgical Resection in Colon Cancer

First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers